Latest Breaking News On - Durvalumab imfinzi - Page 1 : comparemela.com

Durvalumab Plus Guadecitabine Shows PFS Benefit in Cohort of Patients With ccRCC

Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.

Immune Checkpoint Inhibitors for Cancer Treatment

Immune checkpoint inhibitors are promising drugs to treat a variety of cancers and the FDA has approved usage of these checkpoint proteins to treat Cancer.

Vogel Provides Insights on Advanced HCC Management and Expanding Immunotherapy Combinations

Systemic Treatment Plus Embolization Reduces Risk of Death in Patients With Hepatocellular Carcinoma

Compared to embolization alone, the systemic treatment combination nearly doubled progression-free survival among patients with unresectable liver cancer.

Dr Bruno Sangro Discusses Results for EMERALD-1 in Unresectable Hepatocellular Carcinoma

The study’s senior author discusses how the combined mechanisms of action produced benefit in progression-free survival.